ArticleNature medicine2023
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial.
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04788511. Cited by 91 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 3 pooled it
39.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction
PMID 37622681other papers from this trial
Open the trial in the graphWho cites it
91 citing papers in PubMed, 3 syntheses or guidelines pooled it, 179 citations in OpenAlex.
- Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.Diabetes, obesity & metabolism · 2026Pooled it
- Glucagon-like peptide-1 receptor agonists for prevention of heart failure events in type 2 diabetes and/or obesity.ESC heart failure · 2026 · on this mapPooled it
- Pooled it
- Type 2 diabetes in heart failure with preserved and mildly reduced ejection fraction: insights from the REDUCE-LAP-HF II trial.ESC heart failure · 2026Trial
- Semaglutide and Exercise Function in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.JACC. Heart failure · 2025Trial
- Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial.European heart journal · 2025Trial
- Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction.Cardiovascular diabetology · 2025Trial
- Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial.Nature medicine · 2025 · on this mapTrial
- Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial.Circulation · 2024Trial
- Update on clinical heart failure trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial.Bone & joint open · 2026Article
- Glucagon-like Peptide-1 Therapy in Obesity-Related Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Evidence, and Implications.Journal of clinical medicine · 2026Review
- Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.Diabetes, obesity & metabolism · 2026Article
- Exploring the therapeutic potential of GLP-1 receptor agonists in pulmonary arterial hypertension.ERJ open research · 2026Review
- Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit.Circulation. Heart failure · 2026Review
- Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction.International journal of heart failure · 2026Review
- Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness modelling study.Diabetes, obesity & metabolism · 2026Article
- Article
- Heart failure with preserved ejection fraction for the clinician - highlights from the 5th annual Charleston HFpEF conference.Heart failure reviews · 2026Article
- GLP-1-based therapeutics for cardiorenal protection in metabolic diseases.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
28 authors at 20 institutions in 15 countries.
Barry A BorlaugDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-9375-0596
Dalane W KitzmanDepartment of Cardiovascular Medicine and Section on Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Melanie J DaviesDiabetes Research Centre, University of Leicester, Leicester, UK.
Søren RasmussenNovo Nordisk A/S, Søborg, Denmark.
Eric BarrosNovo Nordisk A/S, Søborg, Denmark.ORCID http://orcid.org/0000-0001-6613-4181
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX and Department of Medicine, University of Mississippi, Jackson, MS, USA.
Mette Nygaard EinfeldtNovo Nordisk A/S, Søborg, Denmark.
G Kees HovinghNovo Nordisk A/S, Søborg, Denmark.
Daniél Vega MøllerNovo Nordisk A/S, Søborg, Denmark.
Mark C PetrieSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Sanjiv J ShahDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-5655-8201
Subodh VermaDivision of Cardiac Surgery, Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-4018-8533
Walter AbhayaratnaCollege of Health and Medicine, The Australian National University, Canberra, ACT, Australia.ORCID http://orcid.org/0000-0002-4908-0641
Fozia Z AhmedDivision of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Vijay ChopraClinical Cardiology, Heart Failure and Research, Max Super Specialty Hospital, Saket, New Delhi, India.
Justin EzekowitzUniversity of Alberta, Edmonton, AB, Canada.ORCID http://orcid.org/0000-0002-2724-4086
Michael FuSection of Cardiology, Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden.
Hiroshi ItoDepartment of General Internal Medicine 3, Kawasaki Medical School, Okayama, Japan.
Małgorzata LelonekDepartment of Noninvasive Cardiology, Medical University of Lodz, Lodz, Poland.
Vojtech MelenovskyInstitute for Clinical and Experimental Medicine - IKEM, Prague, Czech Republic.
Julio NúñezHospital Clínico Universitario de Valencia, INCLIVA, Universidad de Valencia, and CIBER Cardiovascular, Valencia, Spain.ORCID http://orcid.org/0000-0003-1672-7119
Eduardo PernaInstituto de Cardiologia J. F. Cabral, Corrientes, Argentina.ORCID http://orcid.org/0000-0002-9977-7623
Morten SchouDepartment of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev, Denmark.
Michele SenniCardiovascular Department, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.ORCID http://orcid.org/0000-0001-5502-7882
Peter van der MeerDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0002-9705-4413
Dirk Von LewinskiDivision of Cardiology, Medical University of Graz, Graz, Austria.ORCID http://orcid.org/0000-0001-9996-6128
Dennis WolfCardiology and Angiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-1525-4348
Mikhail N KosiborodDepartment of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. mkosiborod@saint-lukes.org.ORCID http://orcid.org/0000-0002-3750-9789
Novo Nordisk (Denmark) · DKAustralian National University · AUInstitute of Clinical and Experimental Medicine · CZKawasaki Medical School · JPMax Super Speciality Hospital · INMayo Clinic in Arizona · USMedical University of Graz · ATMedical University of Lodz · PLNorthwestern University · USOspedale Papa Giovanni XXIII · ITSahlgrenska University Hospital · SESaint Luke's Hospital · USSt. Michael's Hospital · CAUniversitat de València · ESUniversity Medical Center Groningen · NLUniversity of Alberta · CAUniversity of Copenhagen · DKUniversity of Freiburg · DEUniversity of Glasgow · GBUniversity of Leicester · GB
Funding
Clinical and Translational Science CenterUL1TR002384 · WEILL MEDICAL COLL OF CORNELL UNIV · 2025 to 2025
$9.8MWake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2002 to 2025
$7.7MPhysical Rehabilitation for Older Patients with Acute HFpEF-The REHAB-HFpEF TrialR01AG078153 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$6.8MHeartShare DeCODE-HF: Data translation center to Combine Omics, Deep phenotyping, and Electronic health records for Heart Failure subtypes and treatment targetsU54HL160273 · NORTHWESTERN UNIVERSITY · 2025 to 2025
$3.3MEXERCISE INTOLERANCE IN ELDERLY DIASTOLIC HEART FAILURER01AG018915 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2001 to 2004
$1.4MPulmonary Hypertension in Left Heart DiseaseR01HL162828 · MAYO CLINIC ROCHESTER · 2025 to 2025
$790kPepper OAIC Coordinating CenterU24AG059624 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$640kWake Forest Atrium HeartShare Clinical CenterU01HL160272 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$529kMayo Clinic HeartShare Clinical CenterU01HL160226 · MAYO CLINIC ROCHESTER · 2025 to 2025
$281kNCATS NIH HHS UL1 TR002384NHLBI NIH HHS R01 HL107577NHLBI NIH HHS R01 HL127028NHLBI NIH HHS R01 HL128526NHLBI NIH HHS R01 HL140731NHLBI NIH HHS R01 HL149423NHLBI NIH HHS R01 HL162828NHLBI NIH HHS U01 HL160226NHLBI NIH HHS U01 HL160272NHLBI NIH HHS U54 HL160273NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG018915NIA NIH HHS R01 AG045551NIA NIH HHS R01 AG078153NIA NIH HHS U01 AG076928NIA NIH HHS U24 AG059624
Abstract
In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise function and reduced body weight in patients with obesity phenotype of heart failure and preserved ejection fraction (HFpEF). This prespecified analysis examined the effects of semaglutide on dual primary endpoints (change in Kansas City Cardiomyopathy Questionnaire-Clinical Summary Score (KCCQ-CSS) and body weight) and confirmatory secondary endpoints (change in 6-minute walk distance (6MWD), hierarchical composite (death, HF events, change in KCCQ-CSS and 6MWD) and change in C-reactive protein (CRP)) across obesity classes I-III (body mass index (BMI) 30.0-34.9 kg m
Indexed as
Heart FailureBody WeightC-Reactive ProteinHumansObesitySemaglutideStroke VolumeWeight LossC-Reactive ProteinSemaglutide
Identifiers
What Socratic holds
Texttitle and abstract
LicenceCC BY
Read underepoch 390
Registered trials
NCT04788511ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.